首页> 外文期刊>Journal of tissue engineering and regenerative medicine >Clinical-scale expansion of adipose-derived stromal cells starting from stromal vascular fraction in a single-use bioreactor: proof of concept for autologous applications
【24h】

Clinical-scale expansion of adipose-derived stromal cells starting from stromal vascular fraction in a single-use bioreactor: proof of concept for autologous applications

机译:在一次性生物反应器中从基质血管分数开始的脂肪源性基质细胞的临床规模扩张:自体应用概念证明

获取原文
获取原文并翻译 | 示例
           

摘要

Adipose-derived stromal cells (ASCs) are adult multipotent cells increasingly used for cell therapy due to their differentiation potential, their paracrine effect and their convenience. ASCs are currently selected from stromal vascular fractions (SVFs) of adipose tissue and expanded in 2D flasks following good manufacturing practices. This process is limited in surface area, labour-intensive and expensive, especially for autologous applications requiring selection and expansion steps for every patient. Closed and automated bioreactors offer an alternative for scalable and cost-effective production of ASCs. This study investigated a single-use stirred-tank bioreactor that can expand ASCs from SVFs on microcarriers. A preliminary microcarrier screening in static and spinner flask conditions was performed to evaluate the best candidate for adhesion, amplification and harvest. The selected microcarrier was used for process development in the bioreactor. The first experiments showed poor selectivity and growth of the ASCs from the SVF (n=2). The process was then adjusted by two means: (1) decreasing the platelet lysate in the medium for enhancing cell adherence; and (2) adding a shear protectant (Pluronic F68). Following these modifications, we demonstrated that the number of population doublings of ASCs from SVFs was not significantly different between the bioreactor and the 2D controls (n=3). In addition, the ASC characterization after culture showed that cells maintained their clonogenic potential, phenotype, differentiation potential and immunosuppressive capacities. This study provides the proof of concept that isolation and amplification of functional ASCs from SVFs can be performed in a stirred-tank bioreactor combined with microcarriers. Copyright (C) 2016 John Wiley & Sons, Ltd.
机译:脂肪衍生的基质细胞(ASCS)是由于其分化潜力而越来越多地用于细胞疗法的成年多电池细胞,它们的旁静脉效应及其便利性。 ASCS目前选自脂肪组织的基质血管分数(SVF),并在良好的制造实践之后在2D瓶中扩展。该过程的表面积有限,劳动密集型且昂贵,特别是对于需要每位患者的选择和扩展步骤的自体应用。封闭和自动化的生物反应器提供了可扩展和经济高效的ASC的替代方案。本研究研究了一种单用搅拌罐生物反应器,可以从微载体上扩展来自SVF的ASC。进行静态和旋转瓶烧瓶条件中的初步微载体筛选,以评估粘附,扩增和收获的最佳候选物。所选微载体用于生物反应器中的工艺发育。第一个实验表明,来自SVF的ASCS的选择性差和生长(n = 2)。然后通过两种方法调节该方法:(1)降低介质中的血小板裂解物以增强细胞粘附; (2)添加剪切保护剂(Pluronic F68)。在这些修改之后,我们证明了生物反应器和2D控制之间的SVFs的ASCS的群体倍增的数量没有显着差异(n = 3)。此外,培养后的ASC表征显示细胞保持其克隆灭绝,表型,分化电位和免疫抑制能力。该研究提供了概念证明,可在与微载体结合微载体的搅拌罐生物反应器中进行分离和扩增的函数ASC。版权所有(c)2016 John Wiley&Sons,Ltd。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号